SI2277890T1 - Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi - Google Patents

Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi

Info

Publication number
SI2277890T1
SI2277890T1 SI200931387T SI200931387T SI2277890T1 SI 2277890 T1 SI2277890 T1 SI 2277890T1 SI 200931387 T SI200931387 T SI 200931387T SI 200931387 T SI200931387 T SI 200931387T SI 2277890 T1 SI2277890 T1 SI 2277890T1
Authority
SI
Slovenia
Prior art keywords
peptide
interest
plasma
life
extending half
Prior art date
Application number
SI200931387T
Other languages
English (en)
Inventor
Naomi Wakabayashi
Seiji Sato
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of SI2277890T1 publication Critical patent/SI2277890T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/63—Motilins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200931387T 2008-05-23 2009-05-22 Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi SI2277890T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008136106 2008-05-23
PCT/JP2009/059464 WO2009142307A1 (ja) 2008-05-23 2009-05-22 目的ペプチドの血漿中半減期延長作用を有するペプチド
EP09750669.5A EP2277890B1 (en) 2008-05-23 2009-05-22 Peptide capable of extending half-life of peptide of interest in plasma

Publications (1)

Publication Number Publication Date
SI2277890T1 true SI2277890T1 (sl) 2016-04-29

Family

ID=41340233

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931387T SI2277890T1 (sl) 2008-05-23 2009-05-22 Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi

Country Status (16)

Country Link
US (1) US8551937B2 (sl)
EP (1) EP2277890B1 (sl)
JP (1) JP5524049B2 (sl)
KR (2) KR101350251B1 (sl)
CN (1) CN101809029B (sl)
BR (1) BRPI0904622A2 (sl)
CA (1) CA2698582C (sl)
CY (1) CY1117478T1 (sl)
DK (1) DK2277890T3 (sl)
ES (1) ES2566830T3 (sl)
HR (1) HRP20160303T1 (sl)
HU (1) HUE028539T2 (sl)
PL (1) PL2277890T3 (sl)
PT (1) PT2277890E (sl)
SI (1) SI2277890T1 (sl)
WO (1) WO2009142307A1 (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3404102T3 (da) 2004-04-21 2021-09-06 Alexion Pharma Inc Knogletilførselskonjugater og fremgangsmåde til anvendelse heraf til målretning af proteiner mod knogle
EP3175863B1 (en) 2009-05-20 2021-12-01 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
EP3189835B1 (en) 2011-02-28 2018-07-25 National Cerebral and Cardiovascular Center Medical agent for suppressing malignant tumor metastasis
KR20140054084A (ko) 2011-08-19 2014-05-08 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약
JPWO2013099376A1 (ja) * 2011-12-26 2015-04-30 国立大学法人福井大学 体外受精における成熟卵子マーカー及びその使用
JPWO2013161895A1 (ja) * 2012-04-25 2015-12-24 第一三共株式会社 骨修復促進剤
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
CN106232141A (zh) * 2014-02-27 2016-12-14 第三共株式会社 针对由给予类固醇诱发的生长不足的药物
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP4162955A1 (en) * 2016-01-08 2023-04-12 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
MX2018013546A (es) * 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
EP3500289A4 (en) 2016-08-18 2020-05-06 Alexion Pharmaceuticals, Inc. METHODS OF TREATING TRACHEOBRONCHOMALACIA
WO2018139464A1 (ja) 2017-01-24 2018-08-02 第一三共株式会社 低身長症治療剤
EP3601314A4 (en) * 2017-03-22 2021-01-13 Pharmain Corporation NPRA AGONISTS, COMPOSITIONS AND CORRESPONDING USES
CA3057502A1 (en) 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
WO2020138948A2 (ko) * 2018-12-26 2020-07-02 아미코젠주식회사 아세틸콜린 수용체 저해 펩타이드 및 이의 용도
BR112021024938A2 (pt) 2019-06-12 2022-01-25 Novartis Ag Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
ATE366813T1 (de) 1999-07-23 2007-08-15 Kenji Kangawa Neue peptide
CN101177455A (zh) * 2001-08-30 2008-05-14 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
BR0212256A (pt) * 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
US20090305969A1 (en) 2005-11-21 2009-12-10 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient
KR20080075530A (ko) 2005-11-21 2008-08-18 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 그렐린, 그 유도체 또는 ＧＨＳ-Ｒ1ａ에 작용하는 물질을유효 성분으로 포함하는 피부 수복 촉진 치료제
BRPI0715809A2 (pt) * 2006-08-11 2014-11-25 Univ Miyazaki Agente terapêutico para a aceleração da restauração do nervo espinhal compreendendo grelina, seus derivados ou substâncias capazes de atuar sobre o ghs-r1a como ingrediente ativo.
WO2008018597A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks

Also Published As

Publication number Publication date
JP5524049B2 (ja) 2014-06-18
US8551937B2 (en) 2013-10-08
HUE028539T2 (en) 2016-12-28
KR20100038236A (ko) 2010-04-13
BRPI0904622A2 (pt) 2016-06-21
DK2277890T3 (en) 2016-02-08
KR20130018965A (ko) 2013-02-25
PT2277890E (pt) 2016-03-31
JPWO2009142307A1 (ja) 2011-09-29
EP2277890B1 (en) 2016-01-06
PL2277890T3 (pl) 2016-06-30
CN101809029B (zh) 2016-06-15
CY1117478T1 (el) 2017-04-26
KR101350251B1 (ko) 2014-01-14
CA2698582A1 (en) 2009-11-26
HRP20160303T1 (hr) 2016-04-22
WO2009142307A1 (ja) 2009-11-26
CN101809029A (zh) 2010-08-18
CA2698582C (en) 2016-09-13
EP2277890A4 (en) 2011-08-24
EP2277890A1 (en) 2011-01-26
ES2566830T3 (es) 2016-04-15
US20100305031A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
PL2277890T3 (pl) Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania
HK1250042A1 (zh) 溶酶體靶向肽及其應用
EP2373679A4 (en) HEPPIDINE MINI PEPTIDES AND METHODS OF USE
GB0914110D0 (en) Peptide libraries
GB0913775D0 (en) Multispecific peptides
EP2249853A4 (en) PEPTIDE PRODRUGS BASED ON ESTERS
HK1214177A1 (zh) 用於癌症的肽治療劑
EP2131390A4 (en) PLASMA PROCESSOR
EP2346521A4 (en) PEPTIDES AND METHODS OF USE
PL2421884T3 (pl) Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje
IL216223A0 (en) Methods of analyzing peptide mixtures
GB0920981D0 (en) Peptides
EP2373272A4 (en) STALL ARTICLE
TWI319863B (en) Plasma display
EP2270141A4 (en) Lacritin PART PEPTIDE
HK1217912A1 (zh) 控釋肽製劑
EP2123666A4 (en) PEPTIDE
EP2478010A4 (en) PART PEPTIDE OF LACRITINE
IL216199A (en) A peptide containing the sequence ednimvtfrnqasr
EP2285827A4 (en) PEPTIDES AND ITS USE
GB0724953D0 (en) Methods of peptide modification
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
ZA201203722B (en) Peptide
EP2504065A4 (en) STABLE MIXTURES AND RELATED METHODS
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS